With the 2016 U.S. presidential election of Donald Trump and the Medicare Access and CHIP Reauthorization Act’s (MACRA) passing, 2017 is shaping up to be a roller-coaster year in the health care industry.
Included in those landmark events, site-neutral payment was solidified and officials launched CMS-driven, oncology-specific payment overhaul efforts.
Although key pressure points in the markets remain mostly unchanged (i.e. surging consumerism), payers and providers could undergo a shift in their responses to such pressures.
However, into what does this culminate for people and cancer patients alike?
(Source: Zachary Hafner, Managed Care Magazine, May 2017)